Medigen Vaccine Biologics (6547)

Currency in TWD
40.70
-0.60(-1.45%)
Closed·
6547 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
6547 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
40.7041.50
52 wk Range
33.7056.60
Key Statistics
Bid/Ask
269.50 / 270.00
Prev. Close
54.1
Open
41.2
Day's Range
40.7-41.5
52 wk Range
33.7-56.6
Volume
1.17M
Average Volume (3m)
1.97M
1-Year Change
-8.02%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6547 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
102.00
Upside
+150.61%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Medigen Vaccine Biologics Company Profile

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. Medigen Vaccine Biologics Corporation was incorporated in 2012 and is headquartered in Zhubei City, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.

Employees
103
Market
Taiwan

Compare 6547 to Peers and Sector

Metrics to compare
6547
Peers
Sector
Relationship
P/E Ratio
−476.3x−24.7x−0.5x
PEG Ratio
−4.900.020.00
Price/Book
3.5x2.8x2.6x
Price / LTM Sales
20.2x30.5x3.3x
Upside (Analyst Target)
150.6%0.0%43.4%
Fair Value Upside
Unlock−12.7%7.1%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 102.00
(+150.61% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-- / 0.08
Revenue / Forecast
-- / 187.00M
EPS Revisions
Last 90 days

6547 Income Statement

FAQ

What Stock Exchange Does Medigen Vaccine Biologics Trade On?

Medigen Vaccine Biologics is listed and trades on the Taipei Exchange stock exchange.

What Is the Stock Symbol for Medigen Vaccine Biologics?

The stock symbol for Medigen Vaccine Biologics is "6547."

What Is the Medigen Vaccine Biologics Market Cap?

As of today, Medigen Vaccine Biologics market cap is 13.38B.

What Is Medigen Vaccine Biologics's Earnings Per Share (TTM)?

The Medigen Vaccine Biologics EPS (TTM) is -0.09.

When Is the Next Medigen Vaccine Biologics Earnings Date?

Medigen Vaccine Biologics will release its next earnings report on 17 Nov 2025.

From a Technical Analysis Perspective, Is 6547 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Medigen Vaccine Biologics Stock Split?

Medigen Vaccine Biologics has split 6 times.

How Many Employees Does Medigen Vaccine Biologics Have?

Medigen Vaccine Biologics has 103 employees.

What is the current trading status of Medigen Vaccine Biologics (6547)?

As of 10 Aug 2025, Medigen Vaccine Biologics (6547) is trading at a price of 40.70, with a previous close of 54.10. The stock has fluctuated within a day range of 40.70 to 41.50, while its 52-week range spans from 33.70 to 56.60.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.